Platinum(II) and technetium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery
作者:Claudio Cassino、Elisabetta Gabano、Mauro Ravera、Giancarlo Cravotto、Giovanni Palmisano、Anne Vessières、Gérard Jaouen、Stefan Mundwiler、Roger Alberto、Domenico Osella
DOI:10.1016/j.ica.2003.12.016
日期:2004.5
method. The structures of the two platinum complexes were energy-minimised by molecular mechanics employing the Amber force field. Both ligands were joined to the [99mTc(CO)3Cl] moiety, 99mTc being the chief γ-emitter employed in nuclear medicine. Unfortunately, piperazine ligand 4 afforded complexes that were unstable under physiological conditions. The RBA values for both ligands and complexes derived
从乙炔雌二醇(1)或更确切地说从其3,17β-双-(三乙基甲硅烷基氧基)衍生物2开始,通过曼尼希氨基甲基化合成了两个包含乙二氨基基序的新配体,即N-甲基-N-(prop-丙-2-炔基-3-(17α-estradiolyl)) - ñ ',ñ '二甲基乙二胺(3)和ñ - (丙-2-炔基-3-(17α-estradiolyl)) - ñ '甲基哌嗪(4)。通过PtI 2制备了相应的铂(II)-丙二醛复合物(7和8)达拉方法的中间体(即5和6)。通过使用琥珀色力场的分子力学,使两个铂配合物的结构能量最小化。两个配体都连接到[ 99m Tc(CO)3 Cl]部分,其中99m Tc是核医学中使用的主要γ发射体。不幸的是,哌嗪配体4提供了在生理条件下不稳定的复合物。衍生自3的配体和复合物的RBA值两种形式的雌激素受体的,均小于1%。这种差的配体识别度可能是由于在生理pH下氨基的部分质子化,使载体相当